Search

ObjectiveThe study was aimed to determine the prevalence and contributing factors of insomnia among patients with bronchial asthma.DesignA multicentre cross-sectional survey was used.SettingThis study was carried out from January to March 2022 in three university comprehensive specialised hospitals in Northwest Ethiopia.Participants422 patients with bronchial asthma were approached of which 93.8% completed the survey.OutcomesThe degree of asthma control and the severity of insomnia were evaluated using the Asthma Control Test and Insomnia Severity Index (ISI), respectively. The characteristics of the participants were presented, arranged and summarised using descriptive statistical analysis, and correlations between predictors and outcome variables were examined using logistic regression. The cut-off point was a p value of 0.05.ResultsParticipants’ ages ranged from 33.6 to 65.2 years on average. Just under three-fourths (71.4%) of the participants had at least one episode of insomnia as per the ISI measurement (score ≥10). The odds of insomnia episodes were about 5.4 and 1.93 times higher in patients with uncontrolled asthma and partially controlled asthma status, with adjusted OR (AOR)=5.4 (95% CI 4.4 to 6.79, pConclusionInsomnia episodes were substantially higher in bronchial patients with asthma. Insomnia is accompanied by asthma severity, and uncontrolled asthma and partially controlled asthma status are the two most determining factors for experiencing sleep disturbance. Furthermore, a prospective follow-up study must determine the real association found between insomnia and asthma control.

ObjectivesThis study was aimed to determine the level of glycaemic control and associated factors in patients with type 2 diabetes mellitus (T2DM) treated with insulin-based therapy.DesignsInstitutional-based multicentre cross-sectional study design was employed to conduct this study.SettingsThe diabetes follow-up clinics of selected hospitals in Northwest Ethiopia.ParticipantsAdult patients with T2DM treated with insulin-based therapy at the selected hospitals who met the eligibility criteria were the study participants.Main outcome measuresGood glycaemic control; when fasting blood glucose (FBG) level ranged from 70 to 130 mg/dL, and FBG 130 mg/dL was considered poor glycaemic control. A logistic regression model was used to identify determinants of poor glycaemic control. A pResultsOf 403 study participants, 54.8% were males with a mean age of 55.03±10.8 years. Though patients with T2DM were treated with insulin-based therapy, most of the participants (72.5%) could not achieve the target FBG. The overall mean FBG was 177.1±54.3, and far from the target glucose level. Patients who could not practise self-monitoring of blood glucose were found more likely to have poor glycaemic control compared with those who practised self-monitoring (pConclusionThis study demonstrated that a significant proportion of the study samples could not achieve glycaemic targets and the average blood glucose was far higher than the recommended glycaemic target level. Insulin initiation and titration, considering the determinants of glycaemic control, could be recommended to achieve target glycaemic levels.